Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutants of cholera toxin as an effective and safe adjuvant for nasal influenza vaccine.

Vaccine - 16 Jul 1999

Hagiwara Y, Komase K, Chen Z, Matsuo K, Suzuki Y, Aizawa C, Kurata T, Tamura S

Abstract excerpt

The effectiveness and safety of mutants of cholera toxin (CT) as an adjuvant for nasal influenza vaccine was examined. Four CT mutants, called CT7 K (Arg to Lys), CT61F (Arg to Phe), CT112 K (Glu to Lys), and CT118E (Glu to Gln), were produced by the replacement of one amino acid at the A1-subunit using site-directed mutagenesis. All these mutants were confirmed to be less toxic than native CT when the toxicity...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adjuvants, Immunologic
Share to Administration, Intranasal

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cholera Toxin

Share to Drug Stability

Share to Immunity, Mucosal

Share to Influenza Vaccines

Share to Orthomyxoviridae Infections

Share to Vaccines, Synthetic

Source

Identifiers

PMID: 10438064
DOI: 10.1016/s0264-410x(99)00135-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutants of cholera toxin as an effective and safe adjuvant for nasal influenza vaccine.PMID 10438064Read ↗

Characterization of protective immune responses induced by nasal influenza vaccine containing mutant cholera toxin as a safe adjuvant (CT112K).Semantic proximity Read ↗

Mutants of Escherichia coli heat-labile enterotoxin as an adjuvant for nasal influenza vaccine.Semantic proximity Read ↗

A second generation of double mutant cholera toxin adjuvants: enhanced immunity without intracellular trafficking.Semantic proximity Read ↗

Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants.Semantic proximity Read ↗

Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity.Semantic proximity Read ↗

Construction of nontoxic derivatives of cholera toxin and characterization of the immunological response against the A subunit.Semantic proximity Read ↗

Genetically manipulated bacterial toxin as a new generation mucosal adjuvant.Semantic proximity Read ↗

IEM101, a naturally attenuated Vibrio cholerae strain as carrier for genetically detoxified derivatives of cholera toxin.Semantic proximity Read ↗

A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A.Semantic proximity Read ↗

A two-codon mutant of cholera toxin lacking ADP-ribosylating activity functions as an effective adjuvant for eliciting mucosal and systemic cellular immune responses to peptide antigens.Semantic proximity Read ↗

Construction and preclinical evaluation of mmCT, a novel mutant cholera toxin adjuvant that can be efficiently produced in genetically manipulated Vibrio cholerae.Semantic proximity Read ↗

Mutant Escherichia coli enterotoxin as a mucosal adjuvant induces specific Th1 responses of CD4+ and CD8+ T cells to nasal killed-bacillus calmette-guerin in mice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.